Cargando…

CD160 receptor in CLL: Current state and future avenues

CD160 is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein expressed on cytotoxic natural killer (NK) cells and T-cell subsets. It plays a crucial role in the activation of NK-cell cytotoxicity and cytokine production. It also modulates the immune system and is involved in some...

Descripción completa

Detalles Bibliográficos
Autores principales: Oumeslakht, Loubna, Aziz, Abdel-ilah, Bensussan, Armand, Ben Mkaddem, Sanae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676924/
https://www.ncbi.nlm.nih.gov/pubmed/36420268
http://dx.doi.org/10.3389/fimmu.2022.1028013
_version_ 1784833698436218880
author Oumeslakht, Loubna
Aziz, Abdel-ilah
Bensussan, Armand
Ben Mkaddem, Sanae
author_facet Oumeslakht, Loubna
Aziz, Abdel-ilah
Bensussan, Armand
Ben Mkaddem, Sanae
author_sort Oumeslakht, Loubna
collection PubMed
description CD160 is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein expressed on cytotoxic natural killer (NK) cells and T-cell subsets. It plays a crucial role in the activation of NK-cell cytotoxicity and cytokine production. It also modulates the immune system and is involved in some pathologies, such as cancer. CD160 is abnormally expressed in B-cell chronic lymphocytic leukemia (CLL) but not expressed in normal B lymphocytes. Its expression in CLL enhances tumor cell proliferation and resistance to apoptosis. CD160 is also a potential prognostic marker for the detection of minimal residual disease (MRD) in CLL, which is important for the clinical management of CLL, the prevention of disease relapse, and the achievement of complete remission. In this review, we present an overview of CD160 and its involvement in the pathophysiology of CLL. We also discuss its use as a prognostic marker for the assessment of MRD in CLL.
format Online
Article
Text
id pubmed-9676924
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96769242022-11-22 CD160 receptor in CLL: Current state and future avenues Oumeslakht, Loubna Aziz, Abdel-ilah Bensussan, Armand Ben Mkaddem, Sanae Front Immunol Immunology CD160 is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein expressed on cytotoxic natural killer (NK) cells and T-cell subsets. It plays a crucial role in the activation of NK-cell cytotoxicity and cytokine production. It also modulates the immune system and is involved in some pathologies, such as cancer. CD160 is abnormally expressed in B-cell chronic lymphocytic leukemia (CLL) but not expressed in normal B lymphocytes. Its expression in CLL enhances tumor cell proliferation and resistance to apoptosis. CD160 is also a potential prognostic marker for the detection of minimal residual disease (MRD) in CLL, which is important for the clinical management of CLL, the prevention of disease relapse, and the achievement of complete remission. In this review, we present an overview of CD160 and its involvement in the pathophysiology of CLL. We also discuss its use as a prognostic marker for the assessment of MRD in CLL. Frontiers Media S.A. 2022-11-07 /pmc/articles/PMC9676924/ /pubmed/36420268 http://dx.doi.org/10.3389/fimmu.2022.1028013 Text en Copyright © 2022 Oumeslakht, Aziz, Bensussan and Ben Mkaddem https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Oumeslakht, Loubna
Aziz, Abdel-ilah
Bensussan, Armand
Ben Mkaddem, Sanae
CD160 receptor in CLL: Current state and future avenues
title CD160 receptor in CLL: Current state and future avenues
title_full CD160 receptor in CLL: Current state and future avenues
title_fullStr CD160 receptor in CLL: Current state and future avenues
title_full_unstemmed CD160 receptor in CLL: Current state and future avenues
title_short CD160 receptor in CLL: Current state and future avenues
title_sort cd160 receptor in cll: current state and future avenues
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676924/
https://www.ncbi.nlm.nih.gov/pubmed/36420268
http://dx.doi.org/10.3389/fimmu.2022.1028013
work_keys_str_mv AT oumeslakhtloubna cd160receptorincllcurrentstateandfutureavenues
AT azizabdelilah cd160receptorincllcurrentstateandfutureavenues
AT bensussanarmand cd160receptorincllcurrentstateandfutureavenues
AT benmkaddemsanae cd160receptorincllcurrentstateandfutureavenues